At the IGTP TODAY
Yesterday morning, a group of second year of scientific baccalaureate students of the Col·legi Cultural de Badalona visited the IGTP. They had the opportunity to see the facilities and learn about basic research pratices.
The European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group Annual Meeting took place on October 24 and 25, organized jointly by the Catalan Institute of Oncology (ICO) and the Germans Trias i Pujol Research Institute (IGTP). Over the two-day event, a series of talks on therapies to fight cancer were held both at the IGTP facilities and online.
The workshop "Advances in Translational Research through EATRIS", organized by the IGTP took place this week and provided a space for researchers to discuss the role of EATRIS as a European infrastructure of translational research.
CARE, the Translational Program in Cancer Research is the first transversal program promoted by the Germans Trias i Pujol Research Institute (IGTP), and it aims to become a bridge for researchers in the field of cancer who want to bring basic and clinical research together, so that the knowledge and the tools generated in the laboratory can benefit the patient.
Dr Bonaventura Clotet, Director of IrsiCaixa and member of the Board of Trustees of the IGTP has been awarded the prestigious 'Premi Nacional de Recerca' in recognition of his contribution to science with his work on infectious diseases, especially HIV and AIDS.
This is the second year that the WiS Group have monitored the scientific activity on Can Ruti Campus.
The Experimental Tuberculosis Group at the IGTP has set up this trial, coordinated from Can Ruti, within the European project H2020 ‘SMA-TB’. The study will evaluate the efficacy and safety of adding acetylsalicylic acid or ibuprofen to the antibiotic treatments applied for tuberculosis. It is a phase II trial which will be carried out in South Africa and Georgia, two of the countries the WHO has in its sights to control this infectious disease. The trial has been prepared in the midst of the pandemic, with the added challenge of coordinating it with the restrictions and different stages of the epidemic in each of the countries involved.
In 2016, the Retrovirology and Clinical Studies group at IrsiCaixa discovered how the absence of the Siglec-1 protein, involved in modulating the immune system, blocks the spread of HIV throughout the body. Now, a study led by the same research group and the Experimental Tuberculosis Unit of the Germans Trias i Pujol Research Institute (IGTP) has shown that, on the other hand, this same deficiency favours the dissemination of Mycobacterium tuberculosis (Mtb), the tuberculosis-causing agent.
The Talents Programme supports research projects in the health sector and despite the pandemic research into other diseases continues. 14 health professionals in all, and 8 of them from Germans Trias i Pujol, have been awarded grants to carry out research projects in the 2020 edition of the programme. The awards represent recognition for young health professionals who are carrying out research activities.
